Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
430.00    6.00 (1.42%)
Bid:
424.50
Ask:
430.00
Spread: 5.50 (1.296%)
Market Cap: £211.48m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Interim Management Statement

26 Oct 2012 07:00

RNS Number : 5898P
Zotefoams PLC
26 October 2012
 



26 October 2012

 

Zotefoams plc

("Zotefoams" or "the Company")

 

Interim Management Statement for the Quarter ended 30 September 2012

 

26 October 2012 - Zotefoams, which manufactures and sells high-performance foams, today announces its interim management statement for the third quarter ended 30 September 2012.

 

Third quarter Polyolefin foam sales increased by approximately 3% in constant currency compared to the same period last year. Sales growth in North America and Rest of World was around 6% while we experienced more modest growth in UK and Continental Europe. The impact of a weaker euro reduced the sterling value of European sales by approximately 10% while there was a small positive impact on sales elsewhere from relative US dollar strength compared with the third quarter in 2011.

 

In the third quarter of 2011 there was high demand for our T-Tubes® insulation products and, due to timing of projects, comparative sales were much lower in 2012. As a result, revenue from our High-Performance Polymers ("HPP") segment was approximately 20% below the same period last year despite an increase in sales of our patented ZOTEK® F fluoropolymer foams. While sales in HPP have historically been subject to short term fluctuations, we remain confident of strong underlying growth in this segment, much of which is to the aviation market.

 

In July and August 2012 MuCell Extrusion LLC ("MEL"), which licenses foaming technology, made important advances within the film and sheet markets. Agreements with Dow Chemical and Styron to license-in their complementary patents have enhanced our ability to offer attractive licences in packaging technology, and activity and interest levels have increased as a direct result. The development pipeline of new projects continues to grow from a small base and in the medium term we expect good progress in conversion of additional signed MEL licences. Currently MEL is a developmental business which is cash generative and we are increasing investment commensurate with our expectations for growth over the coming years.

 

For the third quarter the euro-denominated price of low density polyethylene (LDPE), our main raw material, was at a similar average price compared to the same period last year.

 

The Company continues to progress, with a forward order book into early 2013. Although we are mindful of the uncertain economic environment and the potential for movements in exchange rates to have a translation impact on our reported results, the Board remains confident of a satisfactory outcome for the year and continued progress in the future.

 

 

Enquiries:

Zotefoams plc

0208-664-1600

David Stirling, Managing Director

Clifford Hurst, Finance Director

FTI Consulting

0207-831-3113

Ben Brewerton, John Dineen, Victoria Foster Mitchell

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular material technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces lightweight foams in Croydon, UK and Kentucky, USA for diverse markets worldwide through its global sales force. Zotefoams also owns and licenses patented MuCell® microcellular foam technology from a base in Massachusetts, USA to customers worldwide and sells T-Tubes® advanced insulation systems made from its patented ZOTEK® fluoropolymer foams.

 

www.zotefoams.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUVSBRUSARUAA
Date   Source Headline
6th Jun 20231:34 pmRNSNotification Of Transactions Of Directors/PDMRs
6th Jun 20238:00 amRNSNike Exclusivity Agreement Extension
24th May 202311:40 amRNSResult of the 2023 Annual General Meeting
24th May 20237:00 amRNSTrading Update and Chair Succession
12th May 202310:42 amRNSNotification Of Transactions Of Directors/PDMRs
27th Apr 20237:00 amRNSHigh-performance foam in medical facility doors
26th Apr 20235:44 pmRNSNotification Of Transactions Of Directors/PDMRs
26th Apr 20233:39 pmRNSNotification Of Transactions Of Directors/PDMRs
24th Apr 20235:50 pmRNSReplacement Notice Transactions Of Directors/PDMRs
24th Apr 20234:42 pmRNSNotification Of Transactions Of Directors/PDMRs
21st Apr 20237:00 amRNS2022 Annual Report and Notice of the 2023 AGM
19th Apr 20234:41 pmRNSNotification Of Transactions Of Directors/PDMRs
12th Apr 20231:18 pmRNSNotification Of Transactions Of Directors/PDMRs
27th Mar 20234:35 pmRNSPrice Monitoring Extension
22nd Mar 20231:30 pmRNSHolding(s) in Company
21st Mar 20234:10 pmRNSNotification Of Transactions Of Directors/PDMRs
21st Mar 20234:09 pmRNSHolding(s) in Company
21st Mar 20237:00 amRNSPreliminary Results
14th Mar 20234:58 pmRNSHolding(s) in Company
14th Mar 20233:09 pmRNSNotification Of Transactions Of Directors/PDMRs
28th Feb 20237:00 amRNSAward of AA ESG Ratings assessment
15th Feb 20237:00 amRNSNotice of Results
14th Feb 20233:34 pmRNSNotification Of Transactions Of Directors/PDMRs
3rd Feb 20234:35 pmRNSPrice Monitoring Extension
19th Jan 20237:00 amRNSFull Year Trading Update
17th Jan 20237:00 amRNSChair Succession
12th Jan 202311:18 amRNSNotification Of Transactions Of Directors/PDMRs
15th Dec 20227:00 amRNSTrading Update
13th Dec 20224:03 pmRNSNotification Of Transactions Of Directors/PDMRs
6th Dec 20229:42 amRNSNotification Of Transactions Of Directors/PDMRs
5th Dec 202211:34 amRNSNotification Of Transactions Of Directors/PDMRs
14th Nov 202211:27 amRNSNotification Of Transactions Of Directors/PDMRs
14th Nov 20227:00 amRNSAppointment of Joint Broker
9th Nov 20227:00 amRNSAcquisition of the assets and IP of Refour ApS
17th Oct 202211:31 amRNSNotification Of Transactions Of Directors/PDMRs
13th Oct 20227:00 amRNSTrading Update
12th Oct 20224:02 pmRNSNotification Of Transactions Of Directors/PDMRs
11th Oct 20224:41 pmRNSSecond Price Monitoring Extn
11th Oct 20224:35 pmRNSPrice Monitoring Extension
27th Sep 20227:00 amRNSIndependent Life Cycle Assessment of ReZorce
13th Sep 20223:43 pmRNSDirector/PDMR Shareholding
23rd Aug 20224:35 pmRNSPrice Monitoring Extension
22nd Aug 20224:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20224:36 pmRNSPrice Monitoring Extension
12th Aug 20221:43 pmRNSDirector/PDMR Shareholding
11th Aug 20223:50 pmRNSHolding(s) in Company
9th Aug 20227:00 amRNSInterim Results
2nd Aug 20224:35 pmRNSPrice Monitoring Extension
20th Jul 20224:42 pmRNSSecond Price Monitoring Extn
20th Jul 20224:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.